Comparative Pharmacology
Head-to-head clinical analysis: RAU SED versus RAUVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAU SED versus RAUVAL.
RAU-SED vs RAUVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
None Documented
None Documented
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Antihypertensive
Antihypertensive